{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:14Z","timestamp":1794047474440,"version":"4.8.0"},"reference-count":48,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Immunotherapy has revolutionized treatment for a wide variety of cancers yet its use has been relatively limited in childhood malignancies. With the introduction of bispecific T-cell engagers (BiTE\u00ae) and chimeric antigen T-cell receptor technologies, previously refractory patients have attained remission, including molecularly negative states of disease, thus providing the possibility of long-term cure. Blinatumomab is a widely available CD3-CD19 BiTE that has dramatically changed the landscape of therapy for some children with precursor-B acute lymphoblastic leukemias (B-ALL) and lymphoblastic lymphomas. Challenges remain with using BiTE in a broader population although the appeal of now-confirmed reduced toxicity and deeper molecular remissions suggests that this approach will be an essential part of future treatment of childhood B-ALL. Herein, we review some of the pertinent literature covering clinical trials with blinatumomab and address future approaches and combination trials including BiTE.<\/jats:p>","DOI":"10.3324\/haematol.2023.283818","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T03:43:30Z","timestamp":1717213410000},"page":"1668-1676","source":"Crossref","is-referenced-by-count":22,"title":["Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia"],"prefix":"10.3324","volume":"109","author":[{"given":"Kaylyn Utley","family":"Lyons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"61265","doi-asserted-by":"crossref","unstructured":"Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020; 17(7):418-434.","DOI":"10.1038\/s41571-020-0347-5"},{"key":"61266","doi-asserted-by":"crossref","unstructured":"Hogan LE, Brown PA, Ji L. Children\u2019s Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse. J Clin Oncol. 2023; 41(25):4118-4129.","DOI":"10.1200\/JCO.22.02200"},{"key":"61267","doi-asserted-by":"crossref","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/ refractory acute lymphoblastic leukemia. J Clin Oncol. 2016; 34(36):4381-4389.","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"61268","doi-asserted-by":"crossref","unstructured":"Brown PA, Ji L, Xu X. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021; 325(9):833-842.","DOI":"10.1001\/jama.2021.0669"},{"key":"61269","doi-asserted-by":"crossref","unstructured":"Feucht J, Kayser S, Gorodezki D. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts. Oncotarget. 2016; 7(47):76902-76919.","DOI":"10.18632\/oncotarget.12357"},{"key":"61270","doi-asserted-by":"crossref","unstructured":"Locatelli F, Shah B, Thomas T. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R\/R BCP acute lymphoblastic leukemia: a review. Leuk Lymphoma. 2023; 64(10):1515-1633.","DOI":"10.1080\/10428194.2023.2232496"},{"key":"61271","doi-asserted-by":"crossref","unstructured":"Tian Z, Liu M, Zhang Y. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021; 14(1):75.","DOI":"10.1186\/s13045-021-01084-4"},{"key":"61272","doi-asserted-by":"crossref","unstructured":"Nagorsen D, Kufer P, Baeuerle PA. Blinatumomab: a historical perspective. Pharmacol Ther. 2012; 136(3):334-342.","DOI":"10.1016\/j.pharmthera.2012.07.013"},{"key":"61273","doi-asserted-by":"crossref","unstructured":"Raponi S, De Propris MS, Intoppa S. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011; 52(6):1098-1107.","DOI":"10.3109\/10428194.2011.559668"},{"key":"61274","doi-asserted-by":"crossref","unstructured":"Brandl C, Haas C, d\u2019Argouges S. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother. 2007; 56(10):1551-1563.","DOI":"10.1007\/s00262-007-0298-z"},{"key":"61275","doi-asserted-by":"crossref","unstructured":"Hoffmann P, Hofmeister R, Brischwein K. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005; 115(1):98-104.","DOI":"10.1002\/ijc.20908"},{"key":"61276","doi-asserted-by":"crossref","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015; 373(16):1541-1552.","DOI":"10.1056\/NEJMra1400972"},{"key":"61277","doi-asserted-by":"crossref","unstructured":"Ko RH, Ji L, Barnette P. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010; 28(4):648-654.","DOI":"10.1200\/JCO.2009.22.2950"},{"key":"61278","doi-asserted-by":"crossref","unstructured":"Freyer DR, Devidas M, La M. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children\u2019s Oncology Group. Blood. 2011; 117(11):3010-3015.","DOI":"10.1182\/blood-2010-07-294678"},{"key":"61279","doi-asserted-by":"crossref","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015; 16(1):57-66.","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"61280","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Zugmaier G, Klinger M. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica. 2017; 102(4):e132-e135.","DOI":"10.3324\/haematol.2016.153957"},{"key":"61281","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018; 131(14):1522-1531.","DOI":"10.1182\/blood-2017-08-798322"},{"key":"61282","doi-asserted-by":"crossref","unstructured":"Locatelli F, Zugmaier G, Mergen N. Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020; 10(7):77.","DOI":"10.1038\/s41408-020-00342-x"},{"key":"61283","doi-asserted-by":"crossref","unstructured":"Locatelli F, Zugmaier G, Rizzari C. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021; 325(9):843-854.","DOI":"10.1001\/jama.2021.0987"},{"key":"61284","doi-asserted-by":"crossref","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med. 2023; 388(17):1572-1581.","DOI":"10.1056\/NEJMoa2214171"},{"key":"61285","doi-asserted-by":"crossref","unstructured":"Lange B. The management of neoplastic disorders of haematopoiesis in children with Down\u2019s syndrome. Br J Haematol. 2000; 110(3):512-524.","DOI":"10.1046\/j.1365-2141.2000.02027.x"},{"key":"61286","doi-asserted-by":"crossref","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(36):4134-4140.","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"61287","doi-asserted-by":"crossref","unstructured":"Marrapodi MM, Mascolo A, di Mauro G. The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: a systematic review and meta-analysis. Front Pediatr. 2022; 10:929122.","DOI":"10.3389\/fped.2022.929122"},{"key":"61288","doi-asserted-by":"crossref","unstructured":"Gardner RA, Ceppi F, Rivers J. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019; 134(24):2149-2158.","DOI":"10.1182\/blood.2019001463"},{"key":"61289","doi-asserted-by":"crossref","unstructured":"Choudhry J, Parson M., Wright J. A retrospective review of tocilizumab for the management of blinatumomab (a bispecific T cell engager)-induced cytokine release syndrome (CRS). Blood. 2018; 132(Suppl 1):5211.","DOI":"10.1182\/blood-2018-99-117353"},{"key":"61290","doi-asserted-by":"crossref","unstructured":"Stein AS, Schiller G, Benjamin R. Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2019; 98(1):159-167.","DOI":"10.1007\/s00277-018-3497-0"},{"key":"61291","doi-asserted-by":"crossref","unstructured":"Bhojwani D, Bansal R, Wayne AS. Managing therapy-associated neurotoxicity in children with ALL. Hematology Am Soc Hematol Educ Program. 2021; 2021(1):376-383.","DOI":"10.1182\/hematology.2021000269"},{"key":"61292","doi-asserted-by":"crossref","unstructured":"Aldoss I, Song J, Stiller T. Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol. 2017; 92(9):858-865.","DOI":"10.1002\/ajh.24783"},{"key":"61293","doi-asserted-by":"crossref","unstructured":"Cabannes-Hamy A, Brissot E, Leguay T. High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. Haematologica. 2022; 107(9):2072-2080.","DOI":"10.3324\/haematol.2021.280078"},{"key":"61294","doi-asserted-by":"crossref","unstructured":"Zhao Y, Aldoss I, Qu C. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2021; 137(4):471-484.","DOI":"10.1182\/blood.2020006287"},{"key":"61295","doi-asserted-by":"crossref","unstructured":"Duell J, Dittrich M, Bedke T. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017; 31(10):2181-2190.","DOI":"10.1038\/leu.2017.41"},{"key":"61296","doi-asserted-by":"crossref","unstructured":"Wunderlich M, Manning N, Sexton C. PD-1 inhibition enhances blinatumomab response in a UCB\/PDX model of relapsed pediatric B-cell acute lymphoblastic leukemia. Front Oncol. 2021; 11:642466.","DOI":"10.3389\/fonc.2021.642466"},{"key":"61297","doi-asserted-by":"crossref","unstructured":"Webster J, Luskin MR, Prince GT. Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-cell acute lymphoblastic leukemia (ALL): preliminary results of a phase I study. Blood. 2018; 132(Suppl 1):557.","DOI":"10.1182\/blood-2018-99-111845"},{"key":"61298","doi-asserted-by":"crossref","unstructured":"Goebeler ME, Knop S, Viardot A. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016; 34(10):1104-1011.","DOI":"10.1200\/JCO.2014.59.1586"},{"key":"61299","doi-asserted-by":"crossref","unstructured":"Aldoss I, Otoukesh S, Zhang J. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer. 2022; 128(3):529-535.","DOI":"10.1002\/cncr.33967"},{"key":"61300","doi-asserted-by":"crossref","unstructured":"Pillai V, Muralidharan K, Meng W. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019; 3(22):3539-3549.","DOI":"10.1182\/bloodadvances.2019000692"},{"key":"61301","doi-asserted-by":"crossref","unstructured":"Myers RM, Taraseviciute A, Steinberg SM. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022; 40(9):932-944.","DOI":"10.1200\/JCO.21.01405"},{"key":"61302","doi-asserted-by":"crossref","unstructured":"Zhu M, Wu B, Brandl C. Blinatumomab, a bispecific T-cell engager (BiTE(\u00ae)) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin Pharmacokinet. 2016; 55(10):1271-1288.","DOI":"10.1007\/s40262-016-0405-4"},{"key":"61303","doi-asserted-by":"crossref","unstructured":"Mead MD, Popplewell LL, Subklewe M. Phase I study of the CD19\/CD3 half-life extended BiTE molecule AMG 562 in relapsed\/refractory diffuse large B cell lymphoma, mantle cell lymphoma and follicular lymphoma. Hematol Oncol. 2021; 39(S2):2881.","DOI":"10.1002\/hon.87_2881"},{"key":"61304","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez PM, Zugmaier G, Gordon P. Safety and pharmacokinetics of subcutaneous blinatumomab (SC blinatumomab) for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (R\/R B-ALL); results from a phase 1b study. Blood. 2022; 140(Suppl 1):6122-6124.","DOI":"10.1182\/blood-2022-157117"},{"key":"61305","doi-asserted-by":"crossref","unstructured":"Rao SS, El Abiad JM, Puvanesarajah V. Osteonecrosis in pediatric cancer survivors: epidemiology, risk factors, and treatment. Surg Oncol. 2019; 28:214-221.","DOI":"10.1016\/j.suronc.2019.02.001"},{"key":"61306","doi-asserted-by":"crossref","unstructured":"Lipshultz SE, Lipsitz SR, Sallan SE. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23(12):2629-2636.","DOI":"10.1200\/JCO.2005.12.121"},{"key":"61307","doi-asserted-by":"crossref","unstructured":"Bohler J, Bacher U, Banz Y. Blinatumomab in relapsed\/ refractory Burkitt lymphoma. Cancers (Basel). 2022; 15(1):44.","DOI":"10.3390\/cancers15010044"},{"key":"61308","doi-asserted-by":"crossref","unstructured":"Bannerji R, Allan JN., Arnason JE. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. Blood. 2020; 136(Suppl 1):42-43.","DOI":"10.1182\/blood-2020-136659"},{"key":"61309","doi-asserted-by":"crossref","unstructured":"Ravandi F, Stein AS, Kantarjian HM. A phase 1 first-inhuman study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE\u00ae) antibody construct, in relapsed\/refractory acute myeloid leukemia (R\/R AML). Blood. 2018; 132(Suppl 1):25.","DOI":"10.1182\/blood-2018-99-109762"},{"key":"61310","doi-asserted-by":"crossref","unstructured":"Herrmann M, Krupka C, Deiser K. Development of a bifunctional checkpoint inhibitory T cell engager (CiTE) to reverse adaptive immune escape in AML. Blood. 2018; 132(Suppl 1):4069.","DOI":"10.1182\/blood-2018-99-119624"},{"key":"61311","doi-asserted-by":"crossref","unstructured":"B\u00f6hme M, Kayser S. Immune-based therapeutic strategies for acute myeloid leukemia. Cancers (Basel). 2021; 14(1):105.","DOI":"10.3390\/cancers14010105"},{"key":"61312","doi-asserted-by":"crossref","unstructured":"Rijneveld A, Gradowska P, Bellido M. Blinatumomab added to prephase and consolidation therapy in newly diagnosed precursor B-ALL in adults. A phase II HOVON trial. Hemasphere. 2022; 6(S3):266-267.","DOI":"10.1097\/01.HS9.0000844352.62588.a4"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283818\/76988","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283818\/77041","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11594\/76988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:37Z","timestamp":1794045997000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283818","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}